Client Login
Tesamorelin is a synthetic GHRH analogue, the full 44-amino-acid GHRH sequence with a stabilising N-terminal modification, and among the most extensively characterised growth-hormone-releasing peptides in clinical research. 32mg, with published HPLC purity results. Stored refrigerated at 2–8°C.
Sold for laboratory and research purposes only. Not for human consumption. 18+.
Great Service! i'll sure be sure to reorder
Suzi · Verified buyer · Jul 2026Very informative and helpful pre purchase and post. After care is incredible. Great job, keep it up
Omaad N. · Verified buyer · Jun 2026Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid group added to the N-terminus to improve stability and half-life. It is the only FDA-approved GHRH analogue, authorised under the trade name Egrifta for reduction of excess visceral adipose tissue (VAT) in HIV-infected adults with lipodystrophy - a status that makes it one of the most rigorously characterised GHRH analogues in clinical research.
Research beyond lipodystrophy has explored tesamorelin in the context of cognitive aging. A notable clinical study at Vanderbilt University (2019) examined tesamorelin's effects on memory and executive function in older adults with mild cognitive impairment, finding significant improvements in verbal memory in the treated group - suggesting possible connections between GH axis activity, IGF-1 signalling, and hippocampal function that warrant further investigation.
Tesamorelin has also been investigated in non-alcoholic fatty liver disease (NAFLD) models and in general age-related GH axis decline (somatopause) research, given the well-documented decline in GH secretory amplitude with aging.
Requires refrigeration at 2-8°C. For research purposes only; not approved for therapeutic use in the UAE.
Tesamorelin is a GHRH(1-44) analogue with an N-terminal trans-3-hexenoic acid group that resists DPP-4 degradation and extends stability. In vitro it binds the GHRH receptor on pituitary somatotrophs and is studied as a secretagogue that drives endogenous, pulsatile GH release rather than supplying growth hormone directly.
Downstream research examines IGF-1 signalling and lipid handling, with particular interest in visceral adipose tissue, and it serves as a well-characterised reference GHRH analogue in growth-hormone-axis and metabolic studies. Supplied for in vitro and laboratory research only.
Open to everyone: the research behind each compound, our lab results and how we work.
Tesamorelin is a GHRH(1-44) analogue with an N-terminal trans-3-hexenoic acid group for stability, studied for GH-axis modulation and visceral adipose pathways. For laboratory research only.
HPLC verified with published HPLC purity results, with a Certificate of Analysis on request for each batch.
Next day across the UAE by cold-chain courier, in insulated packaging with ice packs.
All of our products are rigorously tested to pharmaceutical industry standards. This includes full in-house testing and third-party testing across our entire range. Batch test reports and certificates are published on each product page, which you can reach once you are signed in.
Our products are sold strictly for research purposes only. We do not make any medical claims or provide usage guidance.
Due to the nature of our products, we cannot accept returns on any items. For any issues, please message our customer support team.
All products are sold strictly for research and laboratory use only.
Access is restricted to adults 18 and over. We’re unable to grant access.
You won’t be asked again on this device.